Video

Q&A With Gerald Smetana, MD, from Beth Israel Deaconess Medical Center: Weighing Benefits of Vorapaxar for Patients

Author(s):

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

With primary care physicians treating such a broad spectrum of conditions they also have a number of medications they can prescribe to help their patients. While some of these are more beneficial than others it is important to consider which might be more effective for patients.

Gerald Smetana, MD, from Beth Israel Deaconess Medical Center discussed four medications during the American College of Physicians Internal Medicine Meeting in Boston. One medication discussed, Vorapaxar, has been approved to help patients avoid a second cardiovascular event.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.